Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22745294 | 0.88 | NPSR1 (0.49) | USP30ALDH1A1GRM5UCHL1POLB | |
| SCHEMBL19897161 | 0.87 | RIPK1 (0.48) | USP30ALDH1A1UCHL1POLBLMNA | |
| SCHEMBL19897164 | 0.87 | RIPK1 (0.48) | USP30ALDH1A1UCHL1POLBLMNA | |
| SCHEMBL19897159 | 0.87 | RIPK1 (0.48) | USP30ALDH1A1UCHL1POLBLMNA | |
| SCHEMBL31306998 | 0.87 | RIPK1 (0.48) | USP30ALDH1A1UCHL1POLBLMNA | |
| SCHEMBL3052925 | 0.86 | MEN1 (0.53) | ALDH1A1UCHL1LMNATSHRMEN1 | |
| SCHEMBL6012032 | 0.86 | MEN1 (0.53) | ALDH1A1UCHL1LMNATSHRMEN1 | |
| SCHEMBL3052928 | 0.86 | MEN1 (0.53) | ALDH1A1UCHL1LMNATSHRMEN1 | |
| SCHEMBL1396894 | 0.85 | CYP1A2 (0.39) | USP30ALDH1A1GRM5UCHL1POLB | |
| SCHEMBL19935193 | 0.84 | NPC1 (0.42) | USP30ALDH1A1UCHL1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | USP30 3397/4885ALDH1A1 3021/4885GRM5 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.